The results of multicenter study of Rebif 22 micrograms in Russia have been reported. 167 multiple sclerosis patients have received Rebif 22 micrograms three times a week for 1 year. This study provides evidence for reduction of the relapse rate in patients with relapsing/remitting and secondary progressive multiple sclerosis. The tendency to the decrease of the severity of relapses, less need for steroid use and the decrease of EDSS score in patients with relapsing/remitting multiple sclerosis have been shown. In general Rebif 22 micrograms was tolerated well.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
rebif micrograms
12
multiple sclerosis
12
multicenter study
8
patients relapsing/remitting
8
[results multicenter
4
study rebif-22
4
rebif-22 mcg
4
mcg administration
4
administration russia]
4
russia] multicenter
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!